Drugs / 212Pb-DOTAMTATE
212Pb-DOTAMTATE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03466216 | Feb 2018 → Apr 2023 | neuroendocrine neoplasm | Orano Med LLC | Terminated | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05153772 | Dec 2021 → Apr 2025 overdue | neuroendocrine neoplasm | Orano Med LLC | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-20 | Sanofi | Results Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors sanofi.com ↗ |
| 2025-10-08 | Sanofi | Results Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors sanofi.com ↗
AlphaMedix TM ( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors |
All press releases naming this drug 2 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 212Pb-DOTAMTATE | “A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in Subjects With Somatostatin Receptor Expressing Neuroendocrine Tumors” NCT05153772 ↗ |
| Known as | AlphaMedix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03466216 ↗ |
| Known as | Dotamtate lead pb-212 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300858 ↗ |
| Known as | DOTAMTATE PB-212 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300858 ↗ |
| Known as | Lead-212 dotamtate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300858 ↗ |
| Modality | Other / unclassified | “AlphaMedix™ (²¹²Pb-DOTAMTATE) is a radiotherapeutic drug” NCT03466216 ↗ |
| Route | Intravenous | “AlphaMedix™ administered by IV” NCT03466216 ↗ |